search
Back to results

Integrated Psychological Therapy for Chronic Schizophrenia

Primary Purpose

Chronic Schizophrenia

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Integrated Psychological Therapy
Sponsored by
University of the Basque Country (UPV/EHU)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Schizophrenia focused on measuring Chronic schizophrenia, Emotional Management Therapy, Integrated Psychological Therapy

Eligibility Criteria

25 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Having ≥ 5 years since disease onset and aged between 25 and 65 years.
  2. Being in a stable phase of the illness and under psychopharmacological treatment.
  3. Having negative or attenuated positive symptoms.
  4. Failing to achieve premorbid functioning in terms of education, work and/or social life.
  5. Agreeing to participate in the study and giving written informed consent.

Exclusion Criteria:

  • 1. Presenting organic brain pathology. 2. Presenting intellectual developmental disorder according to DSM-5 criteria.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Study procedure

    Treatment as usual

    Arm Description

    An experimental group the psychological treatment includes 50 sessions of integrated psychological therapy (IPT) (focused on attentional skills training, social perception skills training, verbal communication skills, social skills training, interpersonal problems solving skills) and 10 sessions of specific emotional management therapy (EMT), designed for this research and based on the contents developed by Hodel, Kern and Brenner.

    The treatment as usual is pharmacological treatment and activities in a Day Care Center.

    Outcomes

    Primary Outcome Measures

    Frankfurt Complaint Questionnaire (FBF-3)
    (Assessing change)This is a self-report test composed of 98 items measuring the presence of the "basic" symptoms of schizophrenia. These are subjectively experienced disturbances at different domains including perception, thought, processing, language and attention that it could be the neurobiological features of schizophrenia. It contains 10 subscales and 4 factors. We will use a validated version for the Spanish population, in which Cronbach's alpha was above .95 and the test-retest reliability was above .60

    Secondary Outcome Measures

    Screen for Cognitive Impairment in Psychiatry (SCIP)
    (Assessing change)This test assesses cognitive impairment through five areas: immediate and delayed verbal learning, working memory, verbal fluency and information processing speed. It is used for identifying cognitive impairment. The test-retest reliability ranged from 74 to 90 and Cronbach's alpha was 73.
    Wechsler Adult Intelligence Scale-Third Edition (WAIS-III)
    (Assessing change)Short forms of this scale have been designed for patients with schizophrenia . It assess cognitive functioning. Scores on these short forms are correlated (0.91) with the overall intelligence quotient (IQ) of the full scale in clinical patients.
    Wisconsin Card Sorting Test (WCST)
    (Assessing change)This test assesses attention span, planning and execution, and hence is considered a valid measure of executive function. We used the version of the test standardised and benchmarked for the Spanish population by TEA Editions.
    Social Functioning Scale (SFS)
    (Assessing change)We will use the short version of the scale, validated in a Spanish clinical sample, with a Cronbach's alpha of 0.76.
    Lancashire Quality of Life Profile (LQoLP)
    (Assessing change)This instrument assesses patient satisfaction with various aspects of their life, work, leisure time, religion, finances, living situation, safety, family relations, social relations, and health, as well as global wellbeing and self-esteem.

    Full Information

    First Posted
    July 10, 2017
    Last Updated
    September 7, 2017
    Sponsor
    University of the Basque Country (UPV/EHU)
    Collaborators
    Ministerio de Economía y Competitividad, Spain
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03275909
    Brief Title
    Integrated Psychological Therapy for Chronic Schizophrenia
    Official Title
    Integrated Psychological Therapy (IPT) + Emotional Management Therapy (EMT) in Chronic Schizophrenia: Study Protocol for a Randomized Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    July 1, 2011 (Actual)
    Primary Completion Date
    July 30, 2013 (Actual)
    Study Completion Date
    December 31, 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of the Basque Country (UPV/EHU)
    Collaborators
    Ministerio de Economía y Competitividad, Spain

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Background: The chronic phase of schizophrenia (CS) that extremely affects the way people think, feel and act, underlines the need for effective interventions in patients affected by this disorder. The Integrated Psychological Therapy appears in clinical practice guidelines as the reference therapy in the treatment of this type of patients. In this paper authors propose to include in this program a new module focused on Emotional Management Therapy in order to reinforce its effectiveness. The aim of this study is to describe the design of a study protocol for a randomized controlled trial in which the objective is to assess the efficacy of this modified IPT program in patients with CS compared to treatment as usual (pharmacological treatment and social and leisure activities in a Day Care Center). Methods/design: This is a randomized study with pre and post-treatment assessment and with a 6- and 12-month follow-up. Patients are to be randomly assigned to one of two treatments: (1) a experimental group: integrated psychological therapy in conjunction with emotional management therapy (IPT+EMT), composed of 2-hour biweekly 60 group sessions for 32 weeks, in addition to the treatment as usual (TAU), or (2) a control group (treatment as usual). Participants in both groups will be evaluated at baseline (pre-treatment) and at post-treatment after 8 months. The primary outcome will be that patients in the experimental group will show a greater improvement over participants in the control group in reducing symptoms and increasing emotional abilities, as well as in improving their quality of life. The secondary outcome will be that these results will maintain at the 6- and 12-month follow-up in the experimental group.
    Detailed Description
    Background: The chronic phase of schizophrenia (CS) that extremely affects the way people think, feel and act, underlines the need for effective interventions in patients affected by this disorder. The Integrated Psychological Therapy (IPT) appears in clinical practice guidelines as the reference therapy in the treatment of this type of patients. In this paper authors propose to include in this program a new module focused on Emotional Management Therapy (EMT) in order to reinforce its effectiveness. The aim of this study is to describe the design of a study protocol for a randomized controlled trial in which the objective is to assess the efficacy of this modified IPT program in patients with CS compared to treatment as usual (pharmacological treatment and social and leisure activities in a Day Care Center). Methods/design: This is a randomized study with pre and post-treatment assessment and with a 6- and 12-month follow-up. Patients are to be randomly assigned to one of two treatments: (1) a experimental group: integrated psychological therapy in conjunction with emotional management therapy (IPT+EMT), composed of 2-hour biweekly 60 group sessions for 32 weeks, in addition to the treatment as usual (TAU), or (2) a control group (treatment as usual). Participants in both groups will be evaluated at baseline (pre-treatment) and at post-treatment after 8 months. The primary outcome will be that patients in the experimental group will show a greater improvement over participants in the control group in reducing symptoms and increasing emotional abilities, as well as in improving their quality of life. The secondary outcome will be that these results will maintain at the 6- and 12-month follow-up in the experimental group. Discussion: This study provides the description of a clinical trial based on specific psychological intervention (IPT+EMT) for patients with chronic schizophrenia, aiming to improve lasting clinical and functional outcome.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chronic Schizophrenia
    Keywords
    Chronic schizophrenia, Emotional Management Therapy, Integrated Psychological Therapy

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    77 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Study procedure
    Arm Type
    Experimental
    Arm Description
    An experimental group the psychological treatment includes 50 sessions of integrated psychological therapy (IPT) (focused on attentional skills training, social perception skills training, verbal communication skills, social skills training, interpersonal problems solving skills) and 10 sessions of specific emotional management therapy (EMT), designed for this research and based on the contents developed by Hodel, Kern and Brenner.
    Arm Title
    Treatment as usual
    Arm Type
    No Intervention
    Arm Description
    The treatment as usual is pharmacological treatment and activities in a Day Care Center.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Integrated Psychological Therapy
    Other Intervention Name(s)
    Emotional Management Therapy
    Intervention Description
    The psychological treatment includes 50 sessions of integrated psychological therapy focused on attentional skills, social perception skills, verbal communication skills, social skills and interpersonal problems solving skills and 10 sessions of specific emotional management therapy , designed for this research. and based on the contents developed by Hodel, Kern and Brenner
    Primary Outcome Measure Information:
    Title
    Frankfurt Complaint Questionnaire (FBF-3)
    Description
    (Assessing change)This is a self-report test composed of 98 items measuring the presence of the "basic" symptoms of schizophrenia. These are subjectively experienced disturbances at different domains including perception, thought, processing, language and attention that it could be the neurobiological features of schizophrenia. It contains 10 subscales and 4 factors. We will use a validated version for the Spanish population, in which Cronbach's alpha was above .95 and the test-retest reliability was above .60
    Time Frame
    Pretreatment-Posttreatment (8months)-1 month-3 months-6 months-12 months follow-up
    Secondary Outcome Measure Information:
    Title
    Screen for Cognitive Impairment in Psychiatry (SCIP)
    Description
    (Assessing change)This test assesses cognitive impairment through five areas: immediate and delayed verbal learning, working memory, verbal fluency and information processing speed. It is used for identifying cognitive impairment. The test-retest reliability ranged from 74 to 90 and Cronbach's alpha was 73.
    Time Frame
    Pretreatment-Posttreatment (8 months)-1 month-3 months-6 months-12 months follow-up
    Title
    Wechsler Adult Intelligence Scale-Third Edition (WAIS-III)
    Description
    (Assessing change)Short forms of this scale have been designed for patients with schizophrenia . It assess cognitive functioning. Scores on these short forms are correlated (0.91) with the overall intelligence quotient (IQ) of the full scale in clinical patients.
    Time Frame
    Pretreatment-Posttreatment (8 months)-1 month-3 months-6 months-12 months follow-up
    Title
    Wisconsin Card Sorting Test (WCST)
    Description
    (Assessing change)This test assesses attention span, planning and execution, and hence is considered a valid measure of executive function. We used the version of the test standardised and benchmarked for the Spanish population by TEA Editions.
    Time Frame
    Pretreatment-Posttreatment (8 months)-1 month-3 months-6 months-12 months follow-up
    Title
    Social Functioning Scale (SFS)
    Description
    (Assessing change)We will use the short version of the scale, validated in a Spanish clinical sample, with a Cronbach's alpha of 0.76.
    Time Frame
    Pretreatment-Posttreatment-1 month (8 months)-3 months-6 months-12 months follow-up
    Title
    Lancashire Quality of Life Profile (LQoLP)
    Description
    (Assessing change)This instrument assesses patient satisfaction with various aspects of their life, work, leisure time, religion, finances, living situation, safety, family relations, social relations, and health, as well as global wellbeing and self-esteem.
    Time Frame
    Pretreatment-Posttreatment (8 months)-1 month-3 months-6 months-12 months follow-up

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    25 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Having ≥ 5 years since disease onset and aged between 25 and 65 years. Being in a stable phase of the illness and under psychopharmacological treatment. Having negative or attenuated positive symptoms. Failing to achieve premorbid functioning in terms of education, work and/or social life. Agreeing to participate in the study and giving written informed consent. Exclusion Criteria: 1. Presenting organic brain pathology. 2. Presenting intellectual developmental disorder according to DSM-5 criteria.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Karmele Salaberria, Ph.D
    Organizational Affiliation
    Lecturer of School of Psychology
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    to share the study protocol and the clinical study report
    IPD Sharing Time Frame
    2011/2017
    IPD Sharing Access Criteria
    Researchers

    Learn more about this trial

    Integrated Psychological Therapy for Chronic Schizophrenia

    We'll reach out to this number within 24 hrs